Is Marker Therapeutics Stock a Good Investment?
Marker Therapeutics Investment Advice | MRKR |
- Examine Marker Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Marker Therapeutics' leadership team and their track record. Good management can help Marker Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Marker Therapeutics' business and its evolving consumer preferences.
- Compare Marker Therapeutics' performance and market position to its competitors. Analyze how Marker Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Marker Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Marker Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Marker Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Marker Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Marker Therapeutics Stock
Researching Marker Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Marker Therapeutics was now reported as 1.58. The company recorded a loss per share of 1.07. Marker Therapeutics last dividend was issued on the 16th of September 2016. The entity had 1:10 split on the 27th of January 2023.
To determine if Marker Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Marker Therapeutics' research are outlined below:
| Marker Therapeutics generated a negative expected return over the last 90 days | |
| Marker Therapeutics has high historical volatility and very poor performance | |
| Marker Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M). | |
| Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Marker Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates |
Marker Therapeutics Quarterly Accounts Payable |
|
Marker Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Marker Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Marker Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Marker Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Marker Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.39 | -0.26 | 0.13 | 33 | ||
2021-08-10 | 2021-06-30 | -1.17 | -1.3 | -0.13 | 11 | ||
2024-08-14 | 2024-06-30 | -0.43 | -0.29 | 0.14 | 32 | ||
2021-05-12 | 2021-03-31 | -1.45 | -1.6 | -0.15 | 10 | ||
2020-03-12 | 2019-12-31 | -1.26 | -1.1 | 0.16 | 12 | ||
2022-08-11 | 2022-06-30 | -1.27 | -1.1 | 0.17 | 13 | ||
2020-11-09 | 2020-09-30 | -1.43 | -1.6 | -0.17 | 11 | ||
2021-03-09 | 2020-12-31 | -1.6 | -1.8 | -0.2 | 12 |
Know Marker Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Marker Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Marker Therapeutics backward and forwards among themselves. Marker Therapeutics' institutional investor refers to the entity that pools money to purchase Marker Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-06-30 | 11 K | Advisor Group Holdings, Inc. | 2024-06-30 | 7.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6.8 K | Bank Of America Corp | 2024-06-30 | 2.6 K | Tower Research Capital Llc | 2024-06-30 | 1.9 K | Riggs Asset Management Co Inc | 2024-09-30 | 1.2 K | U.s. Bancorp | 2024-06-30 | 839 | Wells Fargo & Co | 2024-06-30 | 232 | Group One Trading, Lp | 2024-06-30 | 178 | Nea Management Company, Llc | 2024-06-30 | 1.1 M | Aisling Capital Management Lp | 2024-09-30 | 314.3 K |
Marker Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 27.66 M.Market Cap |
|
Marker Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (1.04) | (0.99) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (1.00) | (0.95) |
Determining Marker Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Marker Therapeutics is a good buy. For example, gross profit margin measures Marker Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Marker Therapeutics' profitability and make more informed investment decisions.
Evaluate Marker Therapeutics' management efficiency
Marker Therapeutics has return on total asset (ROA) of (0.4087) % which means that it has lost $0.4087 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7174) %, meaning that it created substantial loss on money invested by shareholders. Marker Therapeutics' management efficiency ratios could be used to measure how well Marker Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/23/2024, Return On Tangible Assets is likely to drop to -0.86. In addition to that, Return On Capital Employed is likely to grow to -0.99. At this time, Marker Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 11/23/2024, Net Tangible Assets is likely to grow to about 53.1 M, while Non Current Assets Total are likely to drop 0.00.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.60 | 1.67 | |
| Tangible Book Value Per Share | 1.60 | 1.67 | |
| Enterprise Value Over EBITDA | (2.83) | (2.97) | |
| Price Book Value Ratio | 3.45 | 3.62 | |
| Enterprise Value Multiple | (2.83) | (2.97) | |
| Price Fair Value | 3.45 | 3.62 | |
| Enterprise Value | 16.2 M | 27.1 M |
Understanding the management dynamics of Marker Therapeutics allows us to gauge its ability to sustain growth and profitability. This comprehensive analysis aids in determining the stock's value.
Beta 1.492 |
Basic technical analysis of Marker Stock
As of the 23rd of November, Marker Therapeutics secures the Mean Deviation of 5.13, risk adjusted performance of 0.0087, and Standard Deviation of 7.16. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Marker Therapeutics, as well as the relationship between them. Please verify Marker Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Marker Therapeutics is priced some-what accurately, providing market reflects its recent price of 3.1 per share. Given that Marker Therapeutics has information ratio of (0.02), we recommend you to check Marker Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.Marker Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Marker Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Marker Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Marker Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marker Therapeutics' Outstanding Corporate Bonds
Marker Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Marker Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Marker bonds can be classified according to their maturity, which is the date when Marker Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MARKEL P 5 Corp BondUS570535AQ71 | View | |
| MARKEL P 35 Corp BondUS570535AR54 | View | |
| MARKEL P 43 Corp BondUS570535AS38 | View | |
| US570535AV66 Corp BondUS570535AV66 | View | |
| MKL 6 Corp BondUS570535AW40 | View | |
| US570535AT11 Corp BondUS570535AT11 | View |
Understand Marker Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Marker Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0087 | |||
| Market Risk Adjusted Performance | 0.0048 | |||
| Mean Deviation | 5.13 | |||
| Coefficient Of Variation | (326,593) | |||
| Standard Deviation | 7.16 | |||
| Variance | 51.3 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (1.14) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 37.38 | |||
| Value At Risk | (11.56) | |||
| Potential Upside | 8.87 | |||
| Skewness | 0.8913 | |||
| Kurtosis | 2.62 |
| Risk Adjusted Performance | 0.0087 | |||
| Market Risk Adjusted Performance | 0.0048 | |||
| Mean Deviation | 5.13 | |||
| Coefficient Of Variation | (326,593) | |||
| Standard Deviation | 7.16 | |||
| Variance | 51.3 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.29) | |||
| Total Risk Alpha | (1.14) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 37.38 | |||
| Value At Risk | (11.56) | |||
| Potential Upside | 8.87 | |||
| Skewness | 0.8913 | |||
| Kurtosis | 2.62 |
Consider Marker Therapeutics' intraday indicators
Marker Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Marker Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Marker Therapeutics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 12th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 17th of May 2024 An amendment to the original Schedule 13D filing | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify |
Marker Stock media impact
Far too much social signal, news, headlines, and media speculation about Marker Therapeutics that are available to investors today. That information is available publicly through Marker media outlets and privately through word of mouth or via Marker internal channels. However, regardless of the origin, that massive amount of Marker data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Marker Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Marker Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Marker Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Marker Therapeutics alpha.
Marker Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Marker Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Marker Therapeutics Corporate Management
| Gerald Garrett | Senior Operations | Profile | |
| Juan MD | COO, CoFounder | Profile | |
| Peter MBA | CEO Pres | Profile | |
| Nadia Agopyan | Senior Affairs | Profile | |
| Monic MD | Chief Officer | Profile | |
| Michael Loiacono | Treasurer Secretary | Profile |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.